Cargando…

CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [(68)Ga]Ga-Pentixafor /[(177)Lu]Lu-Pentixather

PURPOSE: CXCR4 (over)expression is found in multiple human cancer types, while expression is low or absent in healthy tissue. In glioblastoma it is associated with a poor prognosis and more extensive infiltrative phenotype. CXCR4 can be targeted by the diagnostic PET agent [(68)Ga]Ga-Pentixafor and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobs, Sarah M., Wesseling, Pieter, de Keizer, Bart, Tolboom, Nelleke, Ververs, F. F. Tessa, Krijger, Gerard C., Westerman, Bart A., Snijders, Tom J., Robe, Pierre A., van der Kolk, Anja G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803771/ https://www.ncbi.nlm.nih.gov/pubmed/33550492 http://dx.doi.org/10.1007/s00259-021-05196-4

Ejemplares similares

[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent
por: Schottelius, Margret, et al.
Publicado: (2017)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo — a comparison to [(68)Ga]pentixafor
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

(68)Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with (177)Lu-PSMA-617
por: de Vries, Lisa H., et al.
Publicado: (2020)

Automated radiosynthesis of [(68)Ga]Ga‐PSMA‐11 and [(177)Lu]Lu‐PSMA‐617 on the iPHASE MultiSyn module for clinical applications
por: Wichmann, Christian W., et al.
Publicado: (2020)

The Dependence of Renal (68)Ga[Ga]-DOTATOC Uptake on Kidney Function and Its Relevance for Peptide Receptor Radionuclide Therapy with (177)Lu[Lu]-DOTATOC
por: Gühne, Falk, et al.
Publicado: (2021)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment
por: Peters, Steffie M. B., et al.
Publicado: (2021)

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with (68)Ga and (177)Lu as Potential Theranostic Agents
por: Salvanou, Evangelia-Alexandra, et al.
Publicado: (2022)

Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
por: Groener, Daniel, et al.
Publicado: (2023)

Predicting [(177)Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [(68)Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
por: Siebinga, Hinke, et al.
Publicado: (2023)

[(68)Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas
por: Breun, Maria, et al.
Publicado: (2019)

Value of Combined PET Imaging with [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [(177)Lu]Lu-PSMA-617 RLT
por: Khreish, Fadi, et al.
Publicado: (2021)

AAZTA(5)/AAZTA(5)-TOC: synthesis and radiochemical evaluation with (68)Ga, (44)Sc and (177)Lu
por: Sinnes, Jean-Philippe, et al.
Publicado: (2019)

Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with (68)Ga and (177)Lu as Potential Theranostic Agent for Colon Cancer
por: Leonte, Radu Anton, et al.
Publicado: (2021)

Ga68-FAPI Imaging and Lu177-FAPI Therapy in a Case of Metastatic Solitary Fibrous Tumor
por: Luthra, Karuna, et al.
Publicado: (2023)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Current Status of (68)Ga-Pentixafor in Solid Tumours
por: Hadebe, Bawinile, et al.
Publicado: (2022)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency
por: Osl, Theresa, et al.
Publicado: (2020)

[(68)Ga]Ga-tilmanocept PET/CT lymphoscintigraphy for sentinel lymph node detection in early-stage oral cavity carcinoma
por: Mahieu, Rutger, et al.
Publicado: (2020)

(68)Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
por: de Keizer, Bart, et al.
Publicado: (2016)

Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-Pentixafor-PET/MRI
por: Haug, Alexander R., et al.
Publicado: (2019)

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Evaluation of thresholding methods for the quantification of [(68)Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Kim, Moon, et al.
Publicado: (2023)

Fully-automated production of [(68)Ga]Ga-PentixaFor on the module Modular Lab-PharmTracer
por: Spreckelmeyer, Sarah, et al.
Publicado: (2020)

Accuracy of PET quantification in [(68)Ga]Ga-pentixafor PET/MR imaging of carotid plaques
por: Rausch, Ivo, et al.
Publicado: (2020)

Early molecular imaging response assessment based on determination of total viable tumor burden in [(68)Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Rosar, Florian, et al.
Publicado: (2021)

Automated synthesis and quality control of [(68)Ga]Ga-PentixaFor using the Gaia/Luna Elysia-Raytest module for CXCR4 PET imaging
por: Daniel, Thomas, et al.
Publicado: (2023)

Diagnosis of Men-I Syndrome on (68)Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE
por: kumar Gupta, Santosh, et al.
Publicado: (2012)

[(68)Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [(177)Lu]DOTATOC PRRT: The “Theragnomics” Concept
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Metallacages with 2,6-dipicolinoylbis(N,N-dialkylthioureas) as novel platforms in nuclear medicine for (68)Ga, (177)Lu and (198)Au
por: Baitullina, Anna, et al.
Publicado: (2023)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hstafv9l993ae4oa2a09mqs7f2